Aspiriant LLC’s Kenvue KVUE Stock Holding History

Aspiriant LLC’s Portfolio KVUE Stock Details KVUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,494	Closed	-$220K	–	303
2024 Q3	$220K	Buy	+9,494	New	+$197K	0.01%	271
2024 Q2	–	Sell	-12,574	Closed	-$270K	–	312
2024 Q1	$270K	Buy	+12,574	New	+$255K	0.01%	265

Other funds holding KVUE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aspiriant LLC's KVUE Position: Q4 2024 in Review

Aspiriant LLC sold out of Kenvue (KVUE) in Q4 2024, closing a stake of 9,494 shares — an estimated $220K sold.

Aspiriant LLC first reported a position in KVUE in Q1 2024 and held it in 2 quarters. The position peaked at $270K in Q1 2024. 1,011 funds tracked by Wall St. Rank hold KVUE as of Q4 2024.

Aspiriant LLC reported no remaining Kenvue position as of Q4 2024 after selling out during the quarter.
Aspiriant LLC sold 9,494 Kenvue shares in Q4 2024, an estimated $220K.
Aspiriant LLC first reported a position in Kenvue in Q1 2024 and held it in 2 quarters.
Aspiriant LLC's Kenvue position peaked at $270K in Q1 2024.
1,011 funds tracked by Wall St. Rank held Kenvue as of Q4 2024.

Based on Aspiriant LLC's 13F filing for Q4 2024, filed 16 Jan 2025.